BioSpace News Archive

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2022 and provide a corporate strategic update on Thursday, August 11, 2022.

United Spinal Association announced the appointment of Vice President of Tech Access, Adina Bradshaw, Director of Chapter Relations, Erin Gildner, and Director of Employment and DEI Programs, Lesly St. Louis to its staff.

The National Institute for Innovation in Manufacturing Biopharmaceuticals is pleased to announce approximately $15.8M in planned project activities through the Institute’s Project Call 5.2 for 14 new projects in technology and workforce development that will help to address key opportunities for innovation in the biopharmaceutical industry.

BioMarker Strategies announced that the journal CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS has published a manuscript by the Company’s scientists entitled “Functional Profiling of Head and Neck/Esophageal Squamous Cell Carcinoma to Predict Cetuximab Response”.

Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the second quarter ended June 30, 2022 and highlighted recent corporate accomplishments.

Surgalign Holdings, Inc., a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, announced financial results for its 2022 second quarter ended June 30, 2022.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the quarter ended June 30, 2022.

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2022, and provided an update on corporate progress.

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2022.

Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, reported financial results for the second quarter ended June 30, 2022.